Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

30.01 -0.24 (-0.79%)
Streaming Delayed Price Updated: 11:14 AM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 Next >
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
From Harmony Biosciences
Via Business Wire
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
From Harmony Biosciences Holdings, Inc.
Via Business Wire
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
From Harmony Biosciences
Via Business Wire
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
Via ACCESSWIRE
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
Via ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
Via ACCESSWIRE
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
From Harmony Biosciences
Via GlobeNewswire
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
From Kahn Swick & Foti, LLC
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.